Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy

Category	Detail
Condition	Genetic lipodystrophy syndromes characterized by generalized or partial lipoatrophy and metabolic complications
Key Mechanisms	Monogenic diseases affecting adipocyte physiology leading to fat loss and insulin resistance-associated complications
Target Population	Adults diagnosed with familial partial lipodystrophy (FPLD) or congenital generalized lipodystrophy (CGL)
Care Setting	Specialized centers within national reference networks for rare diseases and multidisciplinary care involving endocrinologists and other specialists

Health-related quality of life is significantly decreased in patients with genetic lipodystrophy compared to the general population.
High prevalence of moderate or severe depression (41%) and chronic pain (69%) among patients.
Social discrimination is common (73%), including discrimination from health professionals (34%), with significant negative impact on body image and employment.

Clinical recognition of subcutaneous fat loss and abnormal fat distribution as key diagnostic features.
Genetic testing for pathogenic variants in adipocyte-related genes to confirm diagnosis.
Early identification to reduce diagnostic delays estimated around 12 years.

Integrated multidisciplinary approach addressing metabolic, psychological, and social aspects.
Provision of psychosocial support and specialized therapeutic educational programs.
Management of metabolic complications including insulin resistance and cardiometabolic risks.

Regular assessment of physical health, metabolic parameters, and organ complications.
Ongoing evaluation of psychological well-being and social functioning.
Monitoring for depressive symptoms, chronic pain, and treatment burden.

Increased risk of end-organ complications such as acute pancreatitis, hepatic cirrhosis, renal disease, and cardiac insufficiency.
High prevalence of depression, chronic pain, social discrimination, and unemployment due to health issues.
Potential negative impact on self-esteem and body image, especially in women.

Adults with genetic lipodystrophy (FPLD and CGL), predominantly female (84%)

Half of patients have used tranquilizers, sleeping pills, or antidepressants, indicating significant psychological symptom burden.

Implement comprehensive psychosocial support integrated into routine care for patients with genetic lipodystrophy.
Educate healthcare providers to reduce diagnostic delays and improve recognition of lipodystrophy features.
Address social discrimination proactively, including training for health professionals to improve patient interactions.
Regularly assess and manage depressive symptoms and chronic pain to improve quality of life.
Develop and provide specific therapeutic educational programs tailored to the needs of lipodystrophy patients.

Clinical Scorecard: Quality of Life, Social Interaction, and Psychological Health in 109 Adults Diagnosed with Genetic Lipodystrophy